Literature DB >> 18559034

Conservative management of vestibular schwannomas: third review of a 10-year prospective study.

D Hajioff, V V Raut, R M Walsh, A P Bath, M L Bance, A Guha, C H Tator, J A Rutka.   

Abstract

Seventy-two patients with a unilateral vestibular schwannoma have been treated conservatively for a median of 121 months. They have been followed prospectively by serial clinical examination, MRI scans and audiometry. Twenty-five patients (35%, 95% CI: 24-47) failed conservative management and required active intervention during the study. No factors predictive of tumour growth or failure of conservative management could be identified. Seventy-five per cent of failures occurred in the first half of the 10-year study. The median growth rate for all tumours at 10 years was 1 mm/year (range -0.53-7.84). Cerebellopontine angle tumours grew faster (1.4 mm/year) than intracanalicular tumours (0 mm/year, P < 0.01); 92% had growth rates under 2 mm/year. Hearing deteriorated substantially even in tumours that did not grow, but did so faster in tumours that grew significantly (mean deterioration in pure tone average at 0.5, 1, 2 and 3 kHz was 36 dB; speech discrimination scores deteriorated by 40%). Patients who failed conservative management had clinical outcomes that were not different from those who underwent primary treatment without a period of conservative management.

Entities:  

Mesh:

Year:  2008        PMID: 18559034     DOI: 10.1111/j.1749-4486.2008.01705.x

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  26 in total

1.  Long-term hearing preservation after microsurgical excision of vestibular schwannoma.

Authors:  Erika Ann Woodson; Ryan Douglas Dempewolf; Samuel Paul Gubbels; Aaron Thomas Porter; Jacob Jay Oleson; Marlan Rex Hansen; Bruce Jay Gantz
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

2.  Hypofractionated stereotactic radiotherapy of acoustic neuroma: volume changes and hearing results after 89-month median follow-up.

Authors:  Manfred Kranzinger; Franz Zehentmayr; Gerd Fastner; Gerhard Oberascher; Florian Merz; Olaf Nairz; Hassan Rahim; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

3.  Clinical Predictors Leading to Change of Initial Conservative Treatment of 836 Vestibular Schwannomas.

Authors:  Maarten Kleijwegt; Floris Bettink; Martijn Malessy; Hein Putter; Andel van der Mey
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-04

Review 4.  [Vestibular schwannoma - management and microsurgical results].

Authors:  S Rosahl; D Eßer
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

5.  Gamma Knife radiosurgery for vestibular schwannoma: case report and review of the literature.

Authors:  Benjamin J Arthurs; Wayne T Lamoreaux; Neil A Giddings; Robert K Fairbanks; Alexander R Mackay; John J Demakas; Barton S Cooke; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2009-12-18       Impact factor: 2.754

6.  Morbidity and mortality following acoustic neuroma excision in the United States: analysis of racial disparities during a decade in the radiosurgery era.

Authors:  Shearwood McClelland; Hongfei Guo; Kolawole S Okuyemi
Journal:  Neuro Oncol       Date:  2011-08-19       Impact factor: 12.300

7.  Expectant management of vestibular schwannoma: a retrospective multivariate analysis of tumor growth and outcome.

Authors:  Mark Hughes; Christopher Skilbeck; Shakeel Saeed; Robert Bradford
Journal:  Skull Base       Date:  2011-09

8.  Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience.

Authors:  Sumit Kapoor; Sachin Batra; Kathryn Carson; John Shuck; Siddharth Kharkar; Rahul Gandhi; Juan Jackson; Jan Wemmer; Stephanie Terezakis; Ori Shokek; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-29       Impact factor: 7.038

Review 9.  What is the Required Frequency of MRI Scanning in the Wait and Scan Management?

Authors:  Thomas Somers; Romain Kania; Jerome Waterval; Tony Van Havenbergh
Journal:  J Int Adv Otol       Date:  2018-04       Impact factor: 1.017

Review 10.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.